Healthy volunteers of all ages, races, and genders are needed to continue vaccine development at the Saint Louis University Center for Vaccine Development.
Participation in a vaccine study is voluntary and confidential. All study vaccines and tests are free of charge and volunteers receive compensation for time and travel.
Influenza “flu” continues to be a major threat to human health. Every year, thousands of persons in the US die from complications of influenza infection. Usually the elderly, young children and pregnant women are particularly prone to severe complications, but with some pandemic strains (worldwide spread of disease), profuse inflammation (swelling) in response to lower respiratory infection seems to overly affect the middle aged and younger adult populations. Effective vaccines have been available for the past 50 years, and are currently recommended to be given annually due to the change in the types of flu that circulate over time.
Your child may be eligible to participate if he/she is healthy and 9-17 years old.
The study will last 13 months and will include 7 clinic visits and 2 phone calls.
Risks and benefits will be discussed with volunteers as part of the informed consent process.
The child will be compensated $75 a visit and $10 a phone call.
For more information about the study, please contact the Vaccine Center at 314-977-6333 or 1-866-410-6333 (toll-free) and refer to Study #326, IRB: 258011.
Infection with a flu virus is a major public health threat, because it is able to spread rapidly through populations and affect large numbers of people. It is responsible for about 36,000 deaths each year in the U.S. Many deaths occur among older people. Current flu vaccines protect older people against flu, but not as well as desired. The new flu vaccine contains something called an “adjuvant”, which is something that is mixed with the normal flu vaccine before it is given to a patient. This adjuvant helps the body to have a better immune response to the vaccine, so it is more likely to stop you getting flu. If you participate in this second part of the study, you will receive either the adjuvanted vaccine dose picked in Part 1 or unadjuvanted high dose flu vaccine. The vaccine in this study has a new type of adjuvant; it is not yet approved for use by the Food and Drug Administration (FDA). The FDA approval process for the new flu vaccine starts with this study.
You will be compensated $75 per visit and $10 per phone call for participating.
There are about eight visits and about two phone calls over approximately 12 months as part of this study.
To discuss volunteering, please contact a nurse at 1-866-410-6333 (toll free) or at email@example.com and refer to study # 311B , IRB # 25821.